# DPT02 (NCT04482309)

> A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04482309
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer; Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
- Interventions: Trastuzumab deruxtecan
- Enrollment: 477
- Primary outcome: Objective Response Rate (ORR)

## Commentary we found

- YouTube: 66
- X threads: 65
- Podcasts: 64
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dpt02-nct04482309

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04482309", "email": "<work email>"}; the inbox owner confirms by the emailed link.